摘要
目的:评价胰激肽原酶片治疗早期糖尿病肾病患者的疗效和安全性.方法:将82例早期糖尿病肾病患者随机分成2组,采用糖尿病饮食控制、体育锻炼及根据病情给予口服降糖药物或/和胰岛素治疗,治疗组(42例)加用胰激肽原酶片治疗4周.观察治疗前后尿微量白蛋白与24h尿蛋白定量和不良反应.结果:治疗组治疗前后尿微量白蛋白与24h尿蛋白定量明显降低,差异有统计学意义(P<0.01);对照组治疗前后比较差异无统计学意义(P>0.05);组间比较差异有统计学意义(P<0.01);2组患者无明显的药物不良反应.结论:胰激肽原酶片治疗早期糖尿病肾病患者疗效好,用药安全,可广泛应用于临床.
Objective： To evaluate the efficacy and safety of the pancreatic kininogenase tablets in treating early stage diabetic nephropathy. Methods： 82 early stage diabetic nephropathy patients were divided randomly into 2 groups, In addition to dietary control, physical exercise, and administrating with oral anti-diabetic drugs according to the condition and/or insulin treatment, pancreatic kininogenase tablets were given to the patients of the test group for 4 weeks, micro-quantity urine albumin, 24h quantity of urine protein and ADR were observed before and after the treatment. Results： The urine micro-quantity albumin and quantity of 24 h urine protein of the test group deceased after treatment with significant difference （P 〈 0.01）, no significant difference was found of the control group before and after the treatment （P 〉 0.05）, the difference between groups was significant, too （P 〈 0.01）. No distinct ADR was found. Conclusion： Pancreatic kininogenase tablets are effective and safe in the treatment of early stage diabetic nephropathy, which can be widely used in clinical treatment.
出处
《江汉大学学报（自然科学版）》
2009年第3期80-81,共2页
Journal of Jianghan University：Natural Science Edition
关键词
糖尿病
肾病
胰激肽原酶片
疗效
diabetes
nephropathy
pancreatic kininogenase tablets
efficacy
